Regulatory StrategyREG-004Publishedv1.0.0

Pre-Submission Meeting Prep Pack

Walk into every FDA meeting fully prepared

~30s runtime3 evidence sources3 regulatory mappingsUpdated Dec 2025

Summary

Generates structured meeting briefing documents, question strategies, and precedent-based response preparation for FDA Type A, B, and C meetings.

Detailed Description

The Pre-Submission Meeting Prep Pack transforms FDA meeting preparation from an ad hoc process into an evidence-driven practice. It compiles FDA meeting guidance, historical meeting minutes and outcomes, and regulatory precedents to help sponsors prepare comprehensive briefing documents and anticipate FDA feedback.

The pack analyzes your meeting type (Type A, B, or C), development stage, and key questions to generate a structured briefing document outline aligned with FDA expectations. It identifies precedent meeting outcomes for similar development programs and predicts likely FDA positions on your key questions based on historical patterns.

Deliverables include a meeting briefing document template with precedent-informed content, a question-by-question FDA response prediction analysis, and a contingency planning framework for potential FDA pushback scenarios.

Evidence Sources

SourceTypeDescriptionRefresh
FDA Meeting GuidanceREGULATORYFDA guidance on formal meetings including Type A, B, C meeting procedures and content expectationsMonthly
Meeting Outcome PrecedentsCURATEDCurated database of FDA meeting outcomes, minutes, and sponsor questions with FDA responsesQuarterly
CDER Review StandardsREGULATORYCDER review standards and manual of policies and procedures relevant to meeting preparationQuarterly

Regulatory Mapping

FDAFDA-2017-D-5923

Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products

PRIMARY
FDAFDA-2019-D-0268

PDUFA Reauthorization Performance Goals and Procedures

SECONDARY
FDAMAPP 4000.4

Manual of Policies and Procedures: Formal Meetings

SECONDARY

Agent Transparency

When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.

🔍

Evidence Retriever

brew-retriever-v3

Step 1

Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.

Confidence floor: 85%Avg latency: 4-8s
🧬

Domain Analyzer

brew-domain-analyst-v2

Step 2

Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.

Confidence floor: 80%Avg latency: 6-12s
📊

Evidence Synthesizer

brew-synthesizer-v2

Step 3

Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.

Confidence floor: 82%Avg latency: 8-15s

Output Validator

brew-validator-v1

Step 4

Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.

Confidence floor: 90%Avg latency: 2-4s

Sample Outputs

Meeting Briefing Document Template

DOCX

Structured briefing document template with precedent-informed content for FDA meeting

FDA Response Prediction Analysis

PDF

Question-by-question analysis of likely FDA positions based on historical meeting outcomes

Contingency Planning Framework

PDF

Decision trees and contingency strategies for potential FDA pushback scenarios

Deliverables included

  • Meeting briefing document template
  • Question-by-question FDA response predictions
  • Contingency planning for FDA pushback scenarios
  • Meeting logistics and timeline checklist
  • Post-meeting follow-up action framework

Related Disease & Biomarker Mappings

Therapeutic AreaDisease FamilyKey BiomarkersRelevance
Cross-TherapeuticRegulatory Strategy
N/A — regulatory focus
Primary
OncologyAccelerated Approval Programs
ORRDORctDNA response
Secondary

Related Packs in Regulatory Strategy

Version History

v1.0.0CurrentNovember 14, 2025

Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.

v0.9.0October 15, 2025

Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.

v0.1.0September 15, 2025

Initial draft — core evidence retrieval pipeline and output schema established.

Need a Custom Evidence Pack?

Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.

Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.